Eli Lilly-backed Symic raises $30M round as it preps for a pivotal trial
Symic Bio has some big goals set out for the next year. There’s a registration trial to prepare for on the lead program, more work on their other clinical-stage program and preclinical efforts that need to move closer to human studies. And now there’s a $30 million round to pay for these next steps, bringing their total haul over the last three years to $73 million.
The San Francisco-based biotech’s focus is on matrix biology, developing a technology out of Purdue’s bioengineering group that can promote healing after vascular surgery or tamp down on inflammation — and thereby pain — triggered by osteoarthritis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
